FDA okays omalizumab for allergic asthma. (Targets Immunoglobulin E).
Publication: Skin & Allergy News
Publication Date: 01-JUL-03
Author: Mechcatie, Elizabeth
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
The Food and Drug Administration has approved omalizumab as a treatment for people aged 12 years and older with moderate-to-severe persistent asthma.
Omalizumab, the first biotechnology product approved for asthma and the first product approved that targets immunoglobulin E (IgE), will be marketed under the trade name Xolair.
The approved indication is for adults and adolescents aged 12 and older "with moderate-to-severe persistent asthma who have a positive skin test or...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
